Cabozantinib is a multi-kinase inhibitor of VEGFR2, c-MET, AXL, and RET, which was evaluated in a phase 1 trial in association with chemoradiation in newly diagnosed GBM, showing a manageable profile [68], and is under investigation in association with the anti-PD-L1 atezolizumab in a phase 1/2 clinical trial on recurrent GBM (NCT05039281). The gene discussed is AXL; the disease is glioblastoma.